NUTEX HEALTH REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
NUTEX HEALTH REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
- TOTAL REVENUE OF $67.5 MILLION FOR FIRST QUARTER 2024 VS $56.3 MILLION IN 2023, AN INCREASE OF 20%
- HOSPITAL DIVISION VISITS OF 40,068 FOR THE FIRST QUARTER 2024 VS VISITS OF 33,085 IN 2023, AN INCREASE OF 21.1%
- HOSPITAL DIVISION OPERATING INCOME OF $10.5 MILLION FOR FIRST QUARTER 2024 VS $4.8 MILLION IN 2023, AN INCREASE OF 119%
- NET CASH FROM OPERATING ACTIVITIES OF $3.1 MILLION FOR FIRST QUARTER 2024
- CONTINUED FOCUS ON INCREASED CASH FLOW THROUGH REDUCTION IN OPERATING EXPENSES AND PORTFOLIO OPTIMIZATION
- 2024年第一季度的總收入爲6,750萬美元，而2023年爲5,630萬美元，增長了20％
- 2024年第一季度的醫院分部就診量爲40,068人次，而2023年爲33,085人次，增長了21.1％
- 2024年第一季度醫院部門的營業收入爲1,050萬美元，而2023年爲480萬美元，增長了119％
- 2024年第一季度來自經營活動的淨現金爲310萬美元
- 繼續專注於通過減少運營支出和優化投資組合來增加現金流
HOUSTON, May 8, 2024 — Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 21 state-of-the-art micro hospitals in nine states and primary care-centric, risk-bearing physician networks, today announced first quarter 2024 financial results for the three months ended March 31, 2024.
休斯頓，2024年5月8日——Nutex Health Inc.（“NUTEX Health” 或 “公司”）（納斯達克股票代碼：NUTX）是一個由醫生主導、技術支持的綜合醫療保健提供系統，由九個州的21家最先進的微型醫院和以初級保健爲中心、承擔風險的醫生網絡組成，今天公佈了截至2024年3月31日的三個月的2024年第一季度財務業績。
Financial Highlights for the Three Months Ended March 31, 2024:
截至2024年3月31日的三個月的財務摘要：
- Total revenue of $67.5 million as compared to total revenue of $56.3 million for the three months ended March 31, 2023, an increase of approximately 20%. Of this revenue growth, mature hospitals, which are hospitals opened prior to December 31, 2021, increased by 6.7% in 2024 compared to 2023.
- Total visits from the Hospital Division were 40,068 for the first quarter 2024 as compared to 33,085 for the first quarter 2023, an increase of 6,983 or 21.1%. Of this visit growth, mature hospitals increased by 5.3% in 2024 compared to 2023.
- Net loss attributable to Nutex Health Inc. of $0.4 million as compared to net loss attributable to Nutex Health Inc. of $5.1 million for the three months ended March 31, 2023.
- EBITDA of $7.1 million as compared to EBITDA of $0.3 million for the three months ended March 31, 2023.
- Adjusted EBITDA of $4.6 million as compared to Adjusted EBITDA of $2.4 million for the three months ended March 31, 2023, an increase of 92%.
- Net cash from operating activities of $3.1 million.
- As of March 31, 2024, the Company had total assets of $404.3 million, including cash and cash equivalents of $30.0 million and long-term debt of $26.3 million.
- 總收入爲6,750萬美元，而截至2023年3月31日的三個月的總收入爲5,630萬美元，增長了約20％。在這一收入增長中，成熟醫院，即2021年12月31日之前開業的醫院，在2024年與2023年相比增長了6.7％。
- 2024年第一季度，醫院部的總就診人數爲40,068人，而2023年第一季度爲33,085人，增長了6,983人，增長了21.1％。在這一就診量增長中，2024年成熟醫院與2023年相比增長了5.3％。
- 歸屬於Nutex Health Inc.的淨虧損爲40萬美元，而截至2023年3月31日的三個月，歸屬於Nutex Health Inc.的淨虧損爲510萬美元。
- 息稅折舊攤銷前利潤爲710萬美元，而截至2023年3月31日的三個月，息稅折舊攤銷前利潤爲30萬美元。
- 調整後的息稅折舊攤銷前利潤爲460萬美元，而截至2023年3月31日的三個月，調整後的息稅折舊攤銷前利潤爲240萬美元，增長了92％。
- 來自經營活動的淨現金爲310萬美元。
- 截至2024年3月31日，該公司的總資產爲4.043億美元，其中包括3000萬美元的現金和現金等價物以及2630萬美元的長期債務。
Note: EBITDA and Adjusted EBITDA are non-GAAP financial metrics. A reconciliation of non-GAAP to GAAP measures is included below in this earnings release.
注意：息稅折舊攤銷前利潤和調整後息稅折舊攤銷前利潤是非公認會計准則財務指標。本業績中包含了非公認會計准則與公認會計准則指標的對賬。
"We are pleased to report 20% revenue growth, Adjusted EBITDA of $4.6 million and a 119% increase in hospital division operating income to $10.5 million in 2024, with overall Nutex operating income of $1.5 million as opposed to an operating loss of $4.5 million in the same period last year," stated Jon Bates, Chief Financial Officer of Nutex Health.
Nutex Health首席財務官喬恩·貝茨表示：“我們很高興地宣佈，2024年，收入增長了20％，調整後的息稅折舊攤銷前利潤爲460萬美元，醫院部門的營業收入增長了119％，達到1,050萬美元，而去年同期的營業虧損爲450萬美元。”
"We had a solid First Quarter with strong year over year growth. Volume continues to increase at both our mature hospitals as well as the four hospitals that we opened in 2023. Our average payment by insurers of patient claims increased, a trend we are optimistic will persist as we continue to work the NSA claims through the Independent Dispute Resolution process," stated Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health.
“我們的第一季度表現穩健，同比增長強勁。我們的成熟醫院以及我們在2023年開設的四家醫院的數量持續增加。Nutex Health董事長兼首席執行官湯姆·沃醫學博士、工商管理碩士、工商管理碩士、工商管理碩士湯姆·沃表示，隨着我們繼續通過獨立爭議解決程序處理國家安全局的索賠，我們樂觀地認爲，這一趨勢將持續下去。
"Nutex Health has generated net cash from operations and has had positive Adjusted EBITDA for multiple consecutive quarters while growing organically with the opening of five new micro hospitals and growing our population health division in the past 18 months. We believe our balance sheet is strong, with $30.0 million in cash and only $26.3 million in long-term debt," stated Warren Hosseinion, M.D., President of Nutex Health.
“Nutex Health通過運營產生了淨現金，調整後的息稅折舊攤銷前利潤連續多個季度爲正，同時在過去18個月中，隨着五家新的微型醫院的開業和人口健康部門的增長，Nutex Health實現了有機增長。我們認爲我們的資產負債表強勁，有3000萬美元的現金，只有2630萬美元的長期債務。” Nutex Health總裁沃倫·霍塞尼恩醫學博士說。
For more details on the Company's First Quarter 2024 financial results, please refer to our Quarterly Report on Form 10-Q filed with the U.S. Securities & Exchange Commission and accessible at www.sec.gov.
有關公司2024年第一季度財務業績的更多詳情，請參閱我們向美國證券交易委員會提交的10-Q表季度報告，可在以下網址查閱 www.sec.gov。
| NUTEX HEALTH INC. | ||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||
| (Unaudited) | ||||||
| March 31, 2024 | December 31, 2023 | |||||
| Assets | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $ | 30,006,419 | $ | 22,002,056 | ||
| Accounts receivable | 61,533,245 | 58,624,301 | ||||
| Accounts receivable – related parties | 4,213,847 | 4,152,068 | ||||
| Inventories | 2,975,486 | 3,390,584 | ||||
| Prepaid expenses and other current assets | 1,629,346 | 2,679,394 | ||||
| Total current assets | 100,358,343 | 90,848,403 | ||||
| Property and equipment, net | 80,570,705 | 81,387,649 | ||||
| Operating right-of-use assets | 11,580,253 | 11,853,082 | ||||
| Finance right-of-use assets | 173,920,659 | 176,146,329 | ||||
| Intangible assets, net | 20,102,371 | 20,512,636 | ||||
| Goodwill, net | 17,066,263 | 17,066,263 | ||||
| Other assets | 685,260 | 431,135 | ||||
| Total assets | $ | 404,283,854 | $ | 398,245,497 | ||
| Liabilities and Equity | ||||||
| Current liabilities: | ||||||
| Accounts payable | $ | 17,217,905 | $ | 18,899,196 | ||
| Accounts payable – related parties | 6,856,962 | 6,382,197 | ||||
| Lines of credit | 2,777,128 | 3,371,676 | ||||
| Current portion of long-term debt | 9,388,455 | 10,808,721 | ||||
| Operating lease liabilities, current portion | 1,586,904 | 1,579,987 | ||||
| Finance lease liabilities, current portion | 4,366,696 | 4,315,979 | ||||
| Accrued expenses and other current liabilities | 17,694,134 | 12,955,296 | ||||
| Total current liabilities | 59,888,184 | 58,313,052 | ||||
| Long-term debt, net | 26,308,017 | 26,314,733 | ||||
| Warrant liability | 5,060,810 | – | ||||
| Operating lease liabilities, net | 15,097,284 | 15,479,639 | ||||
| Finance lease liabilities, net | 212,867,062 | 213,886,213 | ||||
| Deferred tax liabilities | 5,050,347 | 5,145,754 | ||||
| Total liabilities | 324,271,704 | 319,139,391 | ||||
| Commitments and contingencies | ||||||
| Equity: | ||||||
| Common stock, $0.001 par value; 950,000,000 shares authorized; 49,719,375 and | 49,719 | 45,112 | ||||
| Additional paid-in capital | 472,405,834 | 470,480,617 | ||||
| Accumulated deficit | (409,436,614) | (409,072,539) | ||||
| Nutex Health Inc. equity | 63,018,939 | 61,453,190 | ||||
| Noncontrolling interests | 16,993,211 | 17,652,916 | ||||
| Total equity | 80,012,150 | 79,106,106 | ||||
| Total liabilities and equity | $ | 404,283,854 | $ | 398,245,497 | ||
| NUTEX 健康公司 | ||||||
| 簡明的合併資產負債表 | ||||||
| （未經審計） | ||||||
| 2024年3月31日 | 2023年12月31日 | |||||
| 資產 | ||||||
| 流動資產： | ||||||
| 現金和現金等價物 | $ | 30,006,419 | $ | 22,002,056 | ||
| 應收賬款 | 61,533,245 | 58,624,301 | ||||
| 應收賬款—關聯方 | 4,213,847 | 4,152,068 | ||||
| 庫存 | 2,975,486 | 3,390,584 | ||||
| 預付費用和其他流動資產 | 1,629,346 | 2,679,394 | ||||
| 流動資產總額 | 100,358,343 | 90,848,403 | ||||
| 財產和設備，淨額 | 80,570,705 | 81,387,649 | ||||
| 運營使用權資產 | 11,580,253 | 11,853,082 | ||||
| 爲使用權資產融資 | 173,920,659 | 176,146,329 | ||||
| 無形資產，淨額 | 20,102,371 | 20,512,636 | ||||
| 商譽，淨額 | 17,066,263 | 17,066,263 | ||||
| 其他資產 | 685,260 | 431,135 | ||||
| 總資產 | $ | 404,283,854 | $ | 398,245,497 | ||
| 負債和權益 | ||||||
| 流動負債： | ||||||
| 應付賬款 | $ | 17,217,905 | $ | 18,899,196 | ||
| 應付賬款—關聯方 | 6,856,962 | 6,382,197 | ||||
| 信貸額度 | 2,777,128 | 3,371,676 | ||||
| 長期債務的當前部分 | 9,388,455 | 10,808,721 | ||||
| 經營租賃負債，流動部分 | 1,586,904 | 1,579,987 | ||||
| 融資租賃負債，流動部分 | 4,366,696 | 4,315,979 | ||||
| 應計費用和其他流動負債 | 17,694,134 | 12,955,296 | ||||
| 流動負債總額 | 59,888,184 | 58,313,052 | ||||
| 長期債務，淨額 | 26,308,017 | 26,314,733 | ||||
| 認股權證責任 | 5,060,810 | — | ||||
| 經營租賃負債，淨額 | 15,097,284 | 15,479,639 | ||||
| 融資租賃負債，淨額 | 212,867,062 | 213,886,213 | ||||
| 遞延所得稅負債 | 5,050,347 | 5,145,754 | ||||
| 負債總額 | 324,271,704 | 319,139,391 | ||||
| 承付款和意外開支 | ||||||
| 股權： | ||||||
| 普通股，面值0.001美元；已授權9.5億股；49,719,375和 | 49,719 | 45,112 | ||||
| 額外的實收資本 | 472,405,834 | 470,480,617 | ||||
| 累計赤字 | (409,436,614) | (409,072,539) | ||||
| Nutex 健康公司股權 | 63,018,939 | 61,453,190 | ||||
| 非控股權益 | 16,993,211 | 17,652,916 | ||||
| 權益總額 | 80,012,150 | 79,106,106 | ||||
| 負債和權益總額 | $ | 404,283,854 | $ | 398,245,497 | ||
| NUTEX HEALTH INC. | ||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||
| (Unaudited) | ||||||
| Three Months Ended March 31, | ||||||
| 2024 | 2023 | |||||
| Revenue: | ||||||
| Hospital division | $ | 60,029,369 | $ | 49,288,164 | ||
| Population health management division | 7,424,418 | 7,041,253 | ||||
| Total revenue | 67,453,787 | 56,329,417 | ||||
| Operating costs and expenses: | ||||||
| Payroll and benefits | 27,003,144 | 25,836,673 | ||||
| Contract services | 11,319,454 | 9,189,331 | ||||
| Medical supplies | 5,321,842 | 4,023,882 | ||||
| Depreciation and amortization | 4,186,202 | 3,993,747 | ||||
| Other | 9,465,967 | 8,438,061 | ||||
| Total operating costs and expenses | 57,296,609 | 51,481,694 | ||||
| Gross profit | 10,157,178 | 4,847,723 | ||||
| Corporate and other costs: | ||||||
| Facilities closing costs | – | 217,266 | ||||
| Stock-based compensation expense | 49,167 | 1,900,000 | ||||
| General and administrative expenses | 8,658,410 | 7,175,544 | ||||
| Total corporate and other costs | 8,707,577 | 9,292,810 | ||||
| Operating income (loss) | 1,449,601 | (4,445,087) | ||||
| Interest expense, net | 4,444,362 | 3,140,089 | ||||
| Gain on warrant liability | (2,600,747) | – | ||||
| Other (income) expense | (241,192) | 247,455 | ||||
| Loss before taxes | (152,822) | (7,832,631) | ||||
| Income tax expense (benefit) | 389,665 | (910,659) | ||||
| Net loss | (542,487) | (6,921,972) | ||||
| Less: net loss attributable to noncontrolling interests | (178,412) | (1,774,693) | ||||
| Net loss attributable to Nutex Health Inc. | $ | (364,075) | $ | (5,147,279) | ||
| Loss per common share: | ||||||
| Basic | $ | (0.01) | $ | (0.12) | ||
| Diluted | $ | (0.01) | $ | (0.12) | ||
| NUTEX 健康公司 | ||||||
| 簡明合併運營報表 | ||||||
| （未經審計） | ||||||
| 截至3月31日的三個月 | ||||||
| 2024 | 2023 | |||||
| 收入： | ||||||
| 醫院部門 | $ | 60,029,369 | $ | 49,288,164 | ||
| 人口健康管理司 | 7,424,418 | 7,041,253 | ||||
| 總收入 | 67,453,787 | 56,329,417 | ||||
| 運營成本和支出： | ||||||
| 工資和福利 | 27,003,144 | 25,836,673 | ||||
| 合同服務 | 11,319,454 | 9,189,331 | ||||
| 醫療用品 | 5,321,842 | 4,023,882 | ||||
| 折舊和攤銷 | 4,186,202 | 3,993,747 | ||||
| 其他 | 9,465,967 | 8,438,061 | ||||
| 運營成本和支出總額 | 57,296,609 | 51,481,694 | ||||
| 毛利 | 10,157,178 | 4,847,723 | ||||
| 公司費用和其他費用： | ||||||
| 設施關閉費用 | — | 217,266 | ||||
| 股票薪酬支出 | 49,167 | 1,900,000 | ||||
| 一般和管理費用 | 8,658,410 | 7,175,544 | ||||
| 公司費用和其他費用總額 | 8,707,577 | 9,292,810 | ||||
| 營業收入（虧損） | 1,449,601 | (4,445,087) | ||||
| 利息支出，淨額 | 4,444,362 | 3,140,089 | ||||
| 認股權證責任收益 | (2,600,747) | — | ||||
| 其他（收入）支出 | (241,192) | 247,455 | ||||
| 稅前虧損 | (152,822) | (7,832,631) | ||||
| 所得稅支出（福利） | 389,665 | (910,659) | ||||
| 淨虧損 | (542,487) | (6,921,972) | ||||
| 減去：歸屬於非控股權益的淨虧損 | (178,412) | (1,774,693) | ||||
| 歸因於 Nutex Health Inc. 的淨虧損 | $ | (364,075) | $ | (5,147,279) | ||
| 每股普通股虧損： | ||||||
| 基本 | $ | (0.01) | $ | (0.12) | ||
| 稀釋 | $ | (0.01) | $ | (0.12) | ||
| NUTEX HEALTH INC. | ||||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||
| (Unaudited) | ||||||
| Three Months Ended March 31, | ||||||
| 2024 | 2023 | |||||
| Cash flows from operating activities: | ||||||
| Net loss | $ | (542,487) | $ | (6,921,972) | ||
| Adjustments to reconcile net loss to net cash from operating activities: | ||||||
| Depreciation and amortization | 4,186,202 | 3,993,747 | ||||
| Gain on warrant liability | (2,600,747) | – | ||||
| Amortization of debt issuance costs | – | 6,738 | ||||
| Stock-based compensation expense | 49,167 | 1,900,000 | ||||
| Deferred tax benefit | (95,407) | (910,659) | ||||
| Debt accretion expense | 365,104 | – | ||||
| Loss on lease termination | – | 58,211 | ||||
| Non-cash lease expense (income) | (102,609) | 40,545 | ||||
| Changes in operating assets and liabilities, net of the effects of acquisitions: | ||||||
| Accounts receivable | (2,908,944) | 6,620,249 | ||||
| Accounts receivable – related party | (61,779) | (100) | ||||
| Inventories | 415,098 | 47,840 | ||||
| Prepaid expenses and other current assets | 795,923 | 1,040,753 | ||||
| Accounts payable | (1,681,291) | (8,565,577) | ||||
| Accounts payable – related party | 474,765 | 9,636 | ||||
| Accrued expenses and other current liabilities | 4,757,864 | 3,732,602 | ||||
| Net cash from operating activities | 3,050,859 | 1,052,013 | ||||
| Cash flows from investing activities: | ||||||
| Acquisitions of property and equipment | (733,323) | (4,376,983) | ||||
| Cash related to deconsolidation of Real Estate Entities | – | (1,039,157) | ||||
| Net cash from investing activities | (733,323) | (5,416,140) | ||||
| Cash flows from financing activities: | ||||||
| Proceeds from lines of credit | – | 49,414 | ||||
| Proceeds from notes payable | 2,915,000 | 7,551,506 | ||||
| Repayments of lines of credit | (594,548) | – | ||||
| Repayments of notes payable | (4,386,398) | (2,209,678) | ||||
| Repayments of finance leases | (968,434) | (936,703) | ||||
| Proceeds from common stock issuance, net issuance costs | 9,202,500 | – | ||||
| Members' contributions | – | 28,000 | ||||
| Members' distributions | (481,293) | (1,537,141) | ||||
| Net cash from financing activities | 5,686,827 | 2,945,398 | ||||
| Net change in cash and cash equivalents | 8,004,363 | (1,418,729) | ||||
| Cash and cash equivalents – beginning of the period | 22,002,056 | 34,255,264 | ||||
| Cash and cash equivalents – end of the period | $ | 30,006,419 | $ | 32,836,535 | ||
| NUTEX 健康公司 | ||||||
| 簡明的合併現金流量表 | ||||||
| （未經審計） | ||||||
| 截至3月31日的三個月 | ||||||
| 2024 | 2023 | |||||
| 來自經營活動的現金流： | ||||||
| 淨虧損 | $ | (542,487) | $ | (6,921,972) | ||
| 爲將淨虧損與經營活動產生的淨現金進行對賬而進行的調整： | ||||||
| 折舊和攤銷 | 4,186,202 | 3,993,747 | ||||
| 認股權證責任收益 | (2,600,747) | — | ||||
| 債務發行成本的攤銷 | — | 6,738 | ||||
| 股票薪酬支出 | 49,167 | 1,900,000 | ||||
| 遞延所得稅優惠 | (95,407) | (910,659) | ||||
| 債務增加費用 | 365,104 | — | ||||
| 租賃終止時的損失 | — | 58,211 | ||||
| 非現金租賃費用（收入） | (102,609) | 40,545 | ||||
| 扣除收購影響的運營資產和負債的變化： | ||||||
| 應收賬款 | (2,908,944) | 6,620,249 | ||||
| 應收賬款—關聯方 | (61,779) | (100) | ||||
| 庫存 | 415,098 | 47,840 | ||||
| 預付費用和其他流動資產 | 795,923 | 1,040,753 | ||||
| 應付賬款 | (1,681,291) | (8,565,577) | ||||
| 應付賬款-關聯方 | 474,765 | 9,636 | ||||
| 應計費用和其他流動負債 | 4,757,864 | 3,732,602 | ||||
| 來自經營活動的淨現金 | 3,050,859 | 1,052,013 | ||||
| 來自投資活動的現金流： | ||||||
| 購置財產和設備 | (733,323) | (4,376,983) | ||||
| 與房地產實體解散相關的現金 | — | (1,039,157) | ||||
| 來自投資活動的淨現金 | (733,323) | (5,416,140) | ||||
| 來自融資活動的現金流： | ||||||
| 來自信貸額度的收益 | — | 49,414 | ||||
| 應付票據的收益 | 2,915,000 | 7,551,506 | ||||
| 信貸額度的還款 | (594,548) | — | ||||
| 應付票據的還款 | (4,386,398) | (2,209,678) | ||||
| 償還融資租賃 | (968,434) | (936,703) | ||||
| 普通股發行收益，淨髮行成本 | 9,202,500 | — | ||||
| 成員的捐款 | — | 28,000 | ||||
| 成員分佈 | (481,293) | (1,537,141) | ||||
| 來自融資活動的淨現金 | 5,686,827 | 2,945,398 | ||||
| 現金和現金等價物的淨變化 | 8,004,363 | (1,418,729) | ||||
| 現金及現金等價物——期初 | 22,002,056 | 34,255,264 | ||||
| 現金及現金等價物——期末 | $ | 30,006,419 | $ | 32,836,535 | ||
Non-GAAP Financial Measures (Unaudited)
非公認會計准則財務指標（未經審計）
EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA are used as a supplemental non-GAAP financial measure by management and external users of our financial statements, such as industry analysts, investors, lenders and rating agencies. We believe EBITDA and Adjusted EBITDA are useful because it allows us to more effectively evaluate our operating performance.
息稅折舊攤銷前利潤（EBITDA）和調整後的 我們的財務報表的管理層和外部用戶，例如行業分析師、投資者、貸款人和評級機構，將息稅折舊攤銷前利潤和調整後息稅折舊攤銷前利潤用作補充性非公認會計准則財務指標。我們認爲，息稅折舊攤銷前利潤和調整後息稅折舊攤銷前利潤很有用，因爲它使我們能夠更有效地評估運營業績。
We define EBITDA as net income (loss) attributable to Nutex Health Inc. plus interest expense, income taxes, depreciation and amortization.
我們將息稅折舊攤銷前利潤定義爲歸屬於Nutex Health Inc.的淨收益（虧損）加上利息支出、所得稅、折舊和攤銷。
We define Adjusted EBITDA as net income (loss) attributable to Nutex Health Inc. plus net interest expense, income taxes, depreciation and amortization, further adjusted for stock-based compensation, certain defined items of expense, any acquisition-related costs and impairments. A reconciliation of net income to EBITDA and Adjusted EBITDA is included below. EBITDA and Adjusted EBITDA are not intended to serve as an alternative to U.S. GAAP measures of performance and may not be comparable to similarly-titled measures presented by other companies.
我們將調整後的息稅折舊攤銷前利潤定義爲歸屬於Nutex Health Inc.的淨收益（虧損）加上淨利息支出、所得稅、折舊和攤銷，並進一步調整了股票薪酬、某些特定支出項目、任何與收購相關的成本和減值。淨收入與息稅折舊攤銷前利潤和調整後息稅折舊攤銷前利潤的對賬如下所示。息稅折舊攤銷前利潤和調整後息稅折舊攤銷前利潤不打算作爲美國公認會計准則績效指標的替代方案，也可能無法與其他公司提出的類似標題的指標進行比較。
| Three Months Ended March 31, | ||||||
| 2024 | 2023 | |||||
| Reconciliation of net loss attributable to Nutex Health Inc. to Adjusted | ||||||
| Net loss attributable to Nutex Health Inc. | $ | (364,075) | $ | (5,147,279) | ||
| Depreciation and amortization | 4,186,202 | 3,993,747 | ||||
| Interest expense, net | 4,444,362 | 3,140,089 | ||||
| Income tax expense (benefit) | 389,665 | (910,659) | ||||
| Allocation to noncontrolling interests | (1,544,173) | (755,310) | ||||
| EBITDA | 7,111,981 | 320,588 | ||||
| Facilities closing costs | – | 217,266 | ||||
| Gain on warrant liability | (2,600,747) | – | ||||
| Stock-based compensation expense | 49,167 | 1,900,000 | ||||
| Adjusted EBITDA | $ | 4,560,401 | $ | 2,437,854 | ||
| 截至3月31日的三個月 | ||||||
| 2024 | 2023 | |||||
| 歸屬於Nutex Health Inc.的淨虧損與調整後的對賬 | ||||||
| 歸因於 Nutex Health Inc. 的淨虧損 | $ | (364,075) | $ | (5,147,279) | ||
| 折舊和攤銷 | 4,186,202 | 3,993,747 | ||||
| 利息支出，淨額 | 4,444,362 | 3,140,089 | ||||
| 所得稅支出（福利） | 389,665 | (910,659) | ||||
| 對非控股權益的分配 | (1,544,173) | (755,310) | ||||
| EBITDA | 7,111,981 | 320,588 | ||||
| 設施關閉費用 | — | 217,266 | ||||
| 認股權證責任收益 | (2,600,747) | — | ||||
| 股票薪酬支出 | 49,167 | 1,900,000 | ||||
| 調整後 EBITDA | $ | 4,560,401 | $ | 2,437,854 | ||
About Nutex Health Inc.
關於 Nutex Health Inc
Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division.
Nutex Health Inc.（納斯達克股票代碼：NUTX）總部位於德克薩斯州休斯頓，成立於2011年，是一家醫療保健管理和運營公司，分爲兩個部門：醫院部和人口健康管理部。
The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 21 facilities in nine states.
醫院部擁有、開發和運營創新的醫療保健模式，包括微型醫院、專科醫院和醫院門診部（HOPD）。該部門在九個州擁有並運營21個設施。
The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups. Our cloud-based proprietary technology platform aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers, allowing us to deliver greater quality care more efficiently.
人口健康管理部門擁有並運營獨立醫生協會（IPA）等提供者網絡。通過我們的管理服務組織（MSO），我們爲我們的附屬醫院和醫生團體提供管理、行政和其他支持服務。我們基於雲的專有技術平台彙總了多個設置、信息系統和來源的臨床和索賠數據，以創建患者和提供者的整體視圖，使我們能夠更有效地提供更高質量的護理。
Forward-Looking Statements
前瞻性陳述
Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will", "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended December 31, 2023 under the heading "Risk Factors" in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.
本新聞稿中包含的某些陳述和信息構成1995年《私人證券訴訟法》所指的 “前瞻性陳述”。在本新聞稿中使用 “將”、“可能導致”、“預期”、“將繼續”、“預期”、“估計”、“預計”、“打算”、“目標” 或類似表述的詞語或短語旨在識別1995年《私人證券訴訟改革法》所指的 “前瞻性陳述”。此類陳述受某些已知和未知風險以及不確定性的影響，其中許多風險是公司無法控制的。此類不確定性和風險包括但不限於我們成功執行增長戰略的能力、法律或法規的變化，包括在《無意外法》下實施的臨時最終和最終規則、經濟狀況、對管理層的依賴、對股東的稀釋、資本缺乏、快速增長對公司的影響以及管理層有效應對公司產品和服務增長和需求的能力、新開發的技術、公司的能力競爭，衝突對關聯方交易、監管事務、技術保護、缺乏行業標準、競爭的影響以及公司獲得未來融資的能力感興趣。截至2023年12月31日止年度的10-K表年度報告第一部分第IA項中的 “風險因素” 標題以及不時向美國證券交易委員會提交的其他文件中討論了可能影響未來業績的廣泛因素清單。這些因素可能會對公司的財務業績產生重大不利影響，並可能導致公司未來時期的實際業績與本新聞稿中表達的任何觀點或陳述存在重大差異。
View original content:https://www.prnewswire.com/news-releases/nutex-health-reports-first-quarter-2024-financial-results-302140557.html
SOURCE Nutex Health, Inc.
來源 Nutex Health, Inc.
譯文內容由第三人軟體翻譯。